News

Boehringer Ingelheim withdraws libido drug for women

BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5701 (Published 12 October 2010) Cite this as: BMJ 2010;341:c5701
  1. Jeanne Lenzer
  1. 1New York

The German drug company Boehringer Ingelheim announced on 8 October that it is withdrawing from development its drug to increase female sexual desire.

The drug, flibanserin, which reduces serotonin concentrations while raising those of dopamine and noradrenaline (norepinephrine), was originally intended to be an antidepressant.

The company made the announcement after negative reviews by an advisory panel of the US Food and Drug Administration in June (BMJ 2010;341:c3339 doi:10.1136/bmj.c3339) and a letter issued by the agency in August in response to the company’s new drug application.

Boehringer Ingelheim conducted several studies of the drug in North America …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe